Last Week KemPharm, Inc. (NASDAQ:KMPH) Ratings

May 3, 2018 - By Lena Young

KemPharm, Inc. (NASDAQ:KMPH) Corporate Logo

KemPharm, Inc. (NASDAQ:KMPH) Ratings Coverage

A total of 4 analysts rate KemPharm (NASDAQ:KMPH) as follows: 4 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. The firm has $13.0 highest and $9.0 lowest target. The avg target $10.63 is 106.41% above the last ($5.15) price. (NASDAQ:KMPH) has 6 ratings reports on May 3, 2018 according to StockzIntelligence. On Friday, February 23 Canaccord Genuity maintained KemPharm, Inc. (NASDAQ:KMPH) rating. Canaccord Genuity has “Buy” rating and $11.0 target. In Sunday, February 25 report Oppenheimer maintained it with “Buy” rating and $13.0 target. In Monday, April 2 report Oppenheimer maintained it with “Buy” rating and $1300 target. On Monday, February 26 the rating was maintained by Canaccord Genuity with “Buy”. On Tuesday, January 16 RBC Capital Markets maintained KemPharm, Inc. (NASDAQ:KMPH) with “Buy” rating. On Monday, April 2 the stock of KemPharm, Inc. (NASDAQ:KMPH) has “Buy” rating given by Roth Capital. Listed here are KemPharm, Inc. (NASDAQ:KMPH) PTs and latest ratings.

02/04/2018 Broker: Roth Capital Rating: Buy New Target: $9.5000 Maintain
02/04/2018 Broker: Oppenheimer Rating: Buy New Target: $13.0000 Maintain
26/02/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $7 New Target: $11 Maintain
25/02/2018 Broker: Oppenheimer Rating: Buy New Target: $13.0 Maintain
23/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $11.0 Maintain
16/01/2018 Broker: RBC Capital Markets Rating: Buy New Target: $9.0 Maintain

Lastly it traded at $5.15.It’s uptrending since May 3, 2017 and is 82.56% down. KMPH outperformed by 71.01% the S&P500.

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States.The company has $77.79 million market cap. The Company’s lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain.Last it reported negative earnings. The firm is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders.

KemPharm, Inc. (NASDAQ:KMPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.